250 related articles for article (PubMed ID: 37818566)
1. HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors.
Das T; Khatun S; Jha T; Gayen S
Mini Rev Med Chem; 2024; 24(7):767-784. PubMed ID: 37818566
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability.
Asare Y; Campbell-James TA; Bokov Y; Yu LL; Prestel M; El Bounkari O; Roth S; Megens RTA; Straub T; Thomas K; Yan G; Schneider M; Ziesch N; Tiedt S; Silvestre-Roig C; Braster Q; Huang Y; Schneider M; Malik R; Haffner C; Liesz A; Soehnlein O; Bernhagen J; Dichgans M
Circ Res; 2020 Aug; 127(6):811-823. PubMed ID: 32546048
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Hu S; Cho EH; Lee JY
Diabetes Metab J; 2020 Apr; 44(2):234-244. PubMed ID: 32347025
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
[TBL] [Abstract][Full Text] [Related]
7. Homology modeling and
Elmezayen AD; Yelekçi K
J Biomol Struct Dyn; 2021 Oct; 39(17):6396-6414. PubMed ID: 32715940
[TBL] [Abstract][Full Text] [Related]
8. Inhibition and mechanism of HDAC8 revisited.
Chen K; Zhang X; Wu YD; Wiest O
J Am Chem Soc; 2014 Aug; 136(33):11636-43. PubMed ID: 25060069
[TBL] [Abstract][Full Text] [Related]
9. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.
Yang C; Croteau S; Hardy P
Cell Oncol (Dordr); 2021 Oct; 44(5):997-1017. PubMed ID: 34318404
[TBL] [Abstract][Full Text] [Related]
11. Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement.
Salian-Mehta S; Xu M; McKinsey TA; Tobet S; Wierman ME
J Biol Chem; 2015 May; 290(22):14045-56. PubMed ID: 25873389
[TBL] [Abstract][Full Text] [Related]
12. Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions.
Li L; Liu W; Wang H; Yang Q; Zhang L; Jin F; Jin Y
Cell Death Dis; 2018 May; 9(5):480. PubMed ID: 29691366
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype.
Lecce L; Xu Y; V'Gangula B; Chandel N; Pothula V; Caudrillier A; Santini MP; d'Escamard V; Ceholski DK; Gorski PA; Ma L; Koplev S; Bjørklund MM; Björkegren JL; Boehm M; Bentzon JF; Fuster V; Kim HW; Weintraub NL; Baker AH; Bernstein E; Kovacic JC
J Clin Invest; 2021 Aug; 131(15):. PubMed ID: 34338228
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside IV protects against oxidized low-density lipoprotein-induced injury in human umbilical vein endothelial cells via the histone deacetylase 9 (HDAC9)/NF-κB axis.
Chen D; Du Y; Ye S; Yu J
Environ Toxicol; 2023 Mar; 38(3):534-544. PubMed ID: 36322813
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Rastogi B; Raut SK; Panda NK; Rattan V; Radotra BD; Khullar M
Mol Cell Biochem; 2016 Apr; 415(1-2):183-96. PubMed ID: 26992905
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.
Yuan Z; Peng L; Radhakrishnan R; Seto E
J Biol Chem; 2010 Dec; 285(50):39329-38. PubMed ID: 20947501
[TBL] [Abstract][Full Text] [Related]
18. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
[TBL] [Abstract][Full Text] [Related]
19. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
